Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice

Prolyl hydroxylase domain (PHD) inhibitors, which stimulate erythropoietin production through the activation of hypoxia-inducible factor (HIF), are novel therapeutic agents used for treating renal anemia. Several PHD inhibitors, including enarodustat, are currently undergoing phase 2 or phase 3 clin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of the American Society of Nephrology 2020-03, Vol.31 (3), p.560-577
Hauptverfasser:	Sugahara, Mai, Tanaka, Shinji, Tanaka, Tetsuhiro, Saito, Hisako, Ishimoto, Yu, Wakashima, Takeshi, Ueda, Masatoshi, Fukui, Kenji, Shimizu, Akira, Inagi, Reiko, Yamauchi, Toshimasa, Kadowaki, Takashi, Nangaku, Masaomi
Format:	Artikel
Sprache:	eng
Schlagworte:	Animals Basic Research Chemokine CCL2 - drug effects Chemokine CCL2 - metabolism Diabetes Mellitus, Experimental - drug therapy Diabetes Mellitus, Experimental - metabolism Diabetes Mellitus, Type 2 - complications Diabetes Mellitus, Type 2 - drug therapy Diabetic Nephropathies - metabolism Diabetic Nephropathies - prevention & control Disease Models, Animal Insulin Resistance Metabolic Diseases - etiology Metabolic Diseases - prevention & control Mice Mice, Obese N-substituted Glycines - pharmacology Prolyl Hydroxylases - metabolism Prolyl-Hydroxylase Inhibitors - pharmacology Pyridines - pharmacology Random Allocation Reference Values Treatment Outcome Triazoles - pharmacology
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!